BR9714967B1 - composição farmacêutica a base de ceftiofur. - Google Patents

composição farmacêutica a base de ceftiofur.

Info

Publication number
BR9714967B1
BR9714967B1 BRPI9714967-5A BR9714967A BR9714967B1 BR 9714967 B1 BR9714967 B1 BR 9714967B1 BR 9714967 A BR9714967 A BR 9714967A BR 9714967 B1 BR9714967 B1 BR 9714967B1
Authority
BR
Brazil
Prior art keywords
ceftiofur
pharmaceutical composition
based pharmaceutical
improved
resuspendability
Prior art date
Application number
BRPI9714967-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9714967A (pt
Inventor
Todd P Foster
David L Kiefer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9714967(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9714967A publication Critical patent/BR9714967A/pt
Publication of BR9714967B1 publication Critical patent/BR9714967B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI9714967-5A 1996-12-09 1997-12-03 composição farmacêutica a base de ceftiofur. BR9714967B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions
PCT/US1997/021401 WO1998025621A1 (en) 1996-12-09 1997-12-03 Improved pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BR9714967A BR9714967A (pt) 2001-10-30
BR9714967B1 true BR9714967B1 (pt) 2010-06-29

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9714967-5A BR9714967B1 (pt) 1996-12-09 1997-12-03 composição farmacêutica a base de ceftiofur.

Country Status (22)

Country Link
US (1) US5736151A (de)
EP (1) EP0941095B1 (de)
JP (1) JP2001505910A (de)
KR (1) KR100544248B1 (de)
CN (1) CN100413506C (de)
AT (1) ATE264681T1 (de)
AU (1) AU746666B2 (de)
BR (1) BR9714967B1 (de)
CA (1) CA2269682C (de)
CZ (1) CZ297632B6 (de)
DE (1) DE69728783T2 (de)
DK (1) DK0941095T3 (de)
ES (1) ES2218705T3 (de)
FI (1) FI991302A (de)
HK (1) HK1023292A1 (de)
HU (1) HUP0000564A3 (de)
NO (1) NO325475B1 (de)
NZ (1) NZ336183A (de)
PL (1) PL190662B1 (de)
PT (1) PT941095E (de)
SK (1) SK72399A3 (de)
WO (1) WO1998025621A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
DE60136367D1 (de) * 2000-09-12 2008-12-11 Pharmacia & Upjohn Co Llc Pharmazeutische zusammensetzung mit modifiziertem träger
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
AU2002328168B2 (en) * 2002-08-07 2008-08-21 Merial Ltd. Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
KR100717433B1 (ko) * 2003-03-20 2007-05-14 파마시아 코포레이션 소염제의 분산성 배합물
CN1812814A (zh) * 2003-07-31 2006-08-02 法玛西雅厄普约翰有限责任公司 用于治疗乳腺炎和耳疾病的可分散的药物组合物
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CN101610754A (zh) 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
MX2011005217A (es) 2008-11-19 2011-06-01 Merial Ltd Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencilico.
ES2752034T3 (es) 2012-07-17 2020-04-02 Bayer New Zealand Ltd Formaciones inyectables de antibiótico y sus procedimientos de uso
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2018071810A1 (en) * 2016-10-13 2018-04-19 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL120012C (de) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
WO1987001117A2 (en) * 1985-08-12 1987-02-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
KR0128242B1 (ko) * 1987-11-10 1998-04-02 로버트 에이. 아미테이지 세팔로스포린 항생물질
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
EP0477289A4 (en) * 1989-06-13 1992-07-22 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
CA2155322C (en) * 1993-03-12 2000-02-29 Michael J. Dunn Crystalline ceftiofur free acid

Also Published As

Publication number Publication date
KR100544248B1 (ko) 2006-01-23
CZ297632B6 (cs) 2007-02-14
CA2269682C (en) 2009-04-14
DK0941095T3 (da) 2004-08-02
FI991302A0 (fi) 1999-06-08
EP0941095B1 (de) 2004-04-21
HK1023292A1 (en) 2000-09-08
DE69728783D1 (de) 2004-05-27
SK72399A3 (en) 2000-05-16
ATE264681T1 (de) 2004-05-15
US5736151A (en) 1998-04-07
PT941095E (pt) 2004-08-31
WO1998025621A1 (en) 1998-06-18
CN100413506C (zh) 2008-08-27
PL190662B1 (pl) 2005-12-30
BR9714967A (pt) 2001-10-30
CZ202599A3 (cs) 1999-09-15
DE69728783T2 (de) 2005-03-31
ES2218705T3 (es) 2004-11-16
FI991302A (fi) 1999-06-08
KR20000069360A (ko) 2000-11-25
EP0941095A1 (de) 1999-09-15
NO325475B1 (no) 2008-05-13
AU746666B2 (en) 2002-05-02
HUP0000564A3 (en) 2001-01-29
CA2269682A1 (en) 1998-06-18
NZ336183A (en) 2000-12-22
CN1238690A (zh) 1999-12-15
NO992780D0 (no) 1999-06-08
JP2001505910A (ja) 2001-05-08
AU5452998A (en) 1998-07-03
NO992780L (no) 1999-06-08
HUP0000564A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
BR9714967B1 (pt) composição farmacêutica a base de ceftiofur.
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
PT1263730E (pt) Derivados amina para o tratamento de apoptose
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
NZ505163A (en) Sustained release medicinal compositions comprising an ionic compound with an opposite charge to the ionic active substance
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DK0830350T3 (da) Hidtil ukendte N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[B][1,5]diazepin-3-yl)acetamider
EA200100983A1 (ru) Производные 13-метилэритромицина
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
FR2754258B1 (fr) Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
ATE235472T1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepi - 3-yl)-3-amide
BE1014502A5 (fr) Compositions pharmaceutiques.
ATE196899T1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
ATE236888T1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
TNSN99146A1 (fr) Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69330601D1 (de) Serotoninergische ergolin derivate
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
ATE225787T1 (de) Arylsubstituierte heterocyclische verbindungen
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

B25A Requested transfer of rights approved

Owner name: PAH PANDU LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS PANDU LLC (US)

B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29.06.2020